Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Urothelial Carcinoma Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

12 recruiting trials for Urothelial Carcinoma. Eligibility criteria explained in plain English.

TrialFinderData lists 12 Urothelial Carcinoma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Across the trials that carry a phase, Phase 1 is the largest group at 50% (2 studies); the largest phase groups are Phase 1: 2, Phase 2: 2.

Research is led by Dren Bio (1), Mayo Clinic (1), Institut Claudius Regaud (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Nivolumab (biological, 3 trials), followed by DR-0202, Home Health Encounter.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
12
Total Trials
12
Recruiting Now
0
Phase 3 Trials
10
Sponsors

Track Urothelial Carcinoma trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGPhase 1NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or...

Sponsor: Dren BioEnrolling: 9610 locations
RECRUITINGPhase 2NCT06265285

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access...

This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most...

Sponsor: Mayo ClinicEnrolling: 501 location
RECRUITINGNCT06967961

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

A prospective, proof-of-concept pilot study in patients with metastatic cancers (9 types of cancers are studied) treated at the IUCT-O or possibly in other institutions. Eligible...

Sponsor: Institut Claudius RegaudEnrolling: 4501 location
RECRUITINGNCT04510129

A Multicenter Cancer Biospecimen Collection Study

This study will collect de-identified tumor samples, with correlated clinical/demographic data and tissue histology, from patients selected or scheduled for pre-treatment tumor...

Sponsor: Cofactor Genomics, Inc.Enrolling: 16501 location
RECRUITINGNCT03374267

Registry Platform Urologic Cancer

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform...

Sponsor: iOMEDICO AGEnrolling: 19301 location
RECRUITINGNCT06262516

Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma

The goal of this study is to conduct the first randomized-controlled trial to determine the oncologic efficacy of lymph node dissection in participants with upper tract urothelial...

Sponsor: Case Comprehensive Cancer CenterEnrolling: 944 locations
RECRUITINGNCT05337189

A Multicenter Clinical Trial of Urine DNA Testing for Bladder Cancer in China

The primary objective of this study is to assess the safety and effectiveness of Human Multigene Methylation Detection Kit (Fluorescent PCR Method) for help diagnose bladder...

Sponsor: Creative Biosciences (Guangzhou) Co., Ltd.Enrolling: 4821 location
RECRUITINGNCT06026189

Safely Reduce Cystoscopic Evaluations for Hematuria Patients

The SeARCH-trial assess the clinical impact of a molecular urine test as a 'urine-first' strategy in the diagnostic workup of patients presenting with microscopic hematuria.

Sponsor: Erasmus Medical CenterEnrolling: 11001 location
RECRUITINGNCT06396533

Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE)

This trial aims at investigating the diagnostic ability of a combined diagnostic panel including systematic endoscopic evaluation (SEE), blood-based ctDNA assay, and urine-based...

Sponsor: Fox Chase Cancer CenterEnrolling: 922 locations
RECRUITINGPhase 2NCT06682728

Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the...

Sponsor: University of California, IrvineEnrolling: 231 location
RECRUITINGPhase 1NCT07532902

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

The researchers are doing this study to test the safety of BMS-986504 in combination with standard disease-specific anticancer medication in people with metastatic/advanced...

Sponsor: Memorial Sloan Kettering Cancer CenterEnrolling: 607 locations
RECRUITINGNCT07234968

Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy

Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be...

Sponsor: Thomas Jefferson UniversityEnrolling: 702 locations

Frequently Asked Questions

There are currently 12 clinical trials for Urothelial Carcinoma, with 12 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Urothelial Carcinoma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Urothelial Carcinoma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.